Semaglutide's Effects on Heart and Kidney Health in Type 1 Diabetes
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
This research looks at how a medication called semaglutide might help protect the heart and kidneys in young adults living with type 1 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11112511 on NIH RePORTER |
What this research studies
Even with advanced glucose monitoring, people with type 1 diabetes still face a high risk of heart and kidney problems. Factors like obesity and insulin resistance can make these risks even higher. This project explores whether a medication called semaglutide, which has helped people with type 2 diabetes with their heart health and weight, could also benefit young adults with type 1 diabetes. We want to understand if this medication can improve heart function, reduce artery stiffness, and protect kidney health in this group.
Who could benefit from this research
Good fit: This opportunity is for adults, aged 21 and older, who have type 1 diabetes and may be experiencing or at risk for heart and kidney complications.
Not a fit: Patients who do not have type 1 diabetes or are not at risk for cardiovascular or kidney complications may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to protect the hearts and kidneys of people with type 1 diabetes, potentially reducing serious health complications.
How similar studies have performed: Similar medications (GLP-1RAs) have shown success in improving heart outcomes and supporting weight loss in adults with type 2 diabetes and in animal models, but data for type 1 diabetes is limited.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Nadeau, Kristen Jane — University of Colorado Denver
- Study coordinator: Nadeau, Kristen Jane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.